ANTI-SARS-CoV-2 ANTIBODY

• Main Authors: TANI HIDEKI, HASHIGUCHI TAKAO, OZAWA TATSUHIKO, IKEDA YOSHIKI
• Format: Patent
• Language: English; Japanese
• Published: 02.04.2024
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; VINEGAR; WINE

To provide a novel and effective antibody binding to the spike protein of SARS-CoV-2.SOLUTION: The present invention provides an antibody or its antigen-binding fragment that has a complementarity-determining region (CDR) of the following combination, and binds to the SARS-CoV-2 spike protein. This combination includes CDRH 1, 2, 3 and CDRL 1, 2, 3 with specific amino acid sequences.SELECTED DRAWING: None 【課題】ＳＡＲＳ－ＣｏＶ－２のスパイクタンパク質に結合する新規で有効な抗体の提供。【解決手段】以下の組み合わせの相補性決定領域（ＣＤＲ）を有し，かつ，ＳＡＲＳ－ＣｏＶ－２スパイクタンパク質に結合する抗体又はその抗原結合性断片を提供する：特定のアミノ酸配列からなるＣＤＲＨ１，２，３，ＣＤＲＬ１，２，及び３。【選択図】なし